Skip to main content

Table 1 Characteristics of the patients by cohort

From: Regional lymph node density-based nomogram predicts prognosis in nasopharyngeal carcinoma patients without distant metastases

Variables

Total cohort (n = 610)

Training cohort (n = 425)

Validation cohort (n = 185)

p

Age (years)

46 (37.0–53.0)

46 (37.0–53.0)

46 (38.0–56.0)

0.515

Gender

   

0.822

 Male

453 (74.3)

314 (73.9)

139 (75.1)

 

 Female

157 (25.7)

111 (26.1)

46 (24.9)

 

BMI (kg/m2)

22.1 (20.2–24.2)

22 (20.1–23.9)

22.4 (20.4–24.8)

0.135

Smoking status

   

0.567

 Never

387 (63.4)

266 (62.6)

121 (65.4)

 

 Smoker

223 (36.6)

159 (37.4)

64 (34.6)

 

WHO histologic type

   

0.692

 I/II

69 (11.3)

50 (11.8)

19 (10.3)

 

 III

541 (88.7)

375 (88.2)

166 (89.7)

 

T classification

   

0.324

 T1

0 (0.0)

0 (0.0)

0 (0.0)

 

 T2

260 (42.6)

174 (40.9)

86 (46.5)

 

 T3

193 (31.6)

135 (31.8)

58 (31.4)

 

 T4

157 (25.7)

116 (27.3)

41 (22.2)

 

N classification

   

0.549

 N0

71 (11.6)

49 (11.5)

22 (11.9)

 

 N1

252 (41.3)

181 (42.6)

71 (38.4)

 

 N2

144 (23.6)

102 (24.0)

42 (22.7)

 

 N3

143 (23.4)

93 (21.9)

50 (27.0)

 

Overall stage

   

0.956

 II

129 (21.1)

91 (21.4)

38 (20.5)

 

 III

209 (34.3)

146 (34.4)

63 (34.1)

 

 IVa

272 (44.6)

188 (44.2)

84 (45.4)

 

LLI

   

0.381

 No

499 (81.8)

352 (82.8)

147 (79.5)

 

 Yes

111 (18.2)

73 (17.2)

38 (20.5)

 

Laterality

   

0.917

 Unilateral

216 (35.4)

150 (35.3)

66 (35.7)

 

 Bilateral

239 (39.2)

165 (38.8)

74 (40.0)

 

 None

155 (25.4)

110 (25.9)

45 (24.3)

 

MD (cm)

3.1 (2.0-4.3)

3.1 (1.9–4.2)

3.4 (2.1–4.6)

0.087

RLND

1.2 (1.0-1.7)

1.2 (1.0-1.7)

1.2 (1.0-1.8)

0.482

NG

   

0.496

 No

380 (62.3)

269 (63.3)

111 (60.0)

 

 Yes

230 (37.7)

156 (36.7)

74 (40.0)

 

LNN

   

0.893

 No

403 (66.1)

282 (66.4)

121 (65.4)

 

 Yes

207 (33.9)

143 (33.6)

64 (34.6)

 

ENE

   

0.261

 No

326 (53.4)

234 (55.1)

92 (49.7)

 

 Yes

284 (46.6)

191 (44.9)

93 (50.3)

 

EBV DNA levels (copies/mL)

  

0.043

 < 5000

270 (44.3)

200 (47.1)

70 (37.8)

 

 ≥ 5000

340 (55.7)

225 (52.9)

115 (62.2)

 

WBC (109/L)

6.7 (5.5-8.0)

6.7 (5.6-8.0)

6.5 (5.4-8.0)

0.357

HGB (g/L)

139 (126–150)

138 (126–150)

140 (127–149)

0.933

PLT (109/L)

272 (231–326)

273 (232–324)

269 (225–327)

0.731

NEUT (109/L)

4.0 (3.2-5.0)

4.0 (3.2–5.1)

4.0 (3.1-5.0)

0.366

MONO (109/L)

0.5 (0.4–0.6)

0.5 (0.4–0.6)

0.4 (0.4–0.6)

0.697

LYMPH (109/L)

1.8 (1.4–2.2)

1.8 (1.4–2.2)

1.8 (1.5–2.2)

0.693

ALB (g/L)

41.2 ± 3.4

41.2 ± 3.6

41 ± 3.1

0.507

ALP (U/L)

71.5 (58–88)

72 (59–89)

69 (57–84)

0.221

LDH (U/L)

174 (151–206)

174 (151–208)

173 (150–203)

0.684

Treatment

   

0.507

 RT alone

88 (14.4)

67 (15.8)

21 (11.4)

 

 CCRT

215 (35.2)

146 (34.4)

69 (37.3)

 

 CCRT + IC

264 (43.3)

181 (42.6)

83 (44.9)

 

 CCRT + AC

43 (7.0)

31 (7.3)

12 (6.5)

 
  1. Data are shown as means ± SD, median (IQR), or no. (%)
  2. Abbreviations: SD, standard deviation; IQR, interquartile range; BMI, body mass index; LLI, lower levels involved; MD, nodal maximum dimension; RLND, regional lymph node density; NG, nodal grouping; LNN, lymph node necrosis; ENE, extranodal extension; EBV, Epstein–Barr virus; WBC, white blood cell count; HGB, hemoglobin; PLT, platelet count; NEUT, neutrophil count; MONO, monocyte count; LYMPH, lymphocyte count; ALB, albumin; ALP, alkaline phosphatase; LDH, lactate dehydrogenase; RT, radiotherapy; CCRT, concurrent chemoradiotherapy; IC, induction chemotherapy; AC, adjuvant chemotherapy
Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us